NCCIH Announces Availability of Frequently Asked Questions (FAQs) for HEAL Sickle Cell Disease Pain Management Funding Opportunities RFA-AT-22-004 and RFA-AT-22-005
Notice Number:
NOT-AT-22-006

Key Dates

Release Date:

December 1, 2021

Related Announcements

RFA-AT-22-004 - HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional)

RFA-AT-22-005 - HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)

Issued by

National Center for Complementary and Integrative Health (NCCIH)

Purpose

The purpose of this Notice is to inform potential applicants that a set of responses to frequently asked questions (FAQs) regarding RFA-AT-22-004: HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional) has been posted at the following link: https://www.nccih.nih.gov/grants/frequently-asked-questions-heal-initiative-pragmatic-and-implementation-studies-for-the-management-of-sickle-cell-disease-pain-ug3uh3-clinical-trials-optional.

In addition, responses to FAQs for RFA-AT-22-005: HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required) have been posted at the following link: https://www.nccih.nih.gov/grants/frequently-asked-questions-heal-initiative-sickle-cell-disease-pain-management-trials-utilizing-the-pain-management-effectiveness-research-network-cooperative-agreement-ug3uh3-clinical-trial-required.

Inquiries

Please direct all inquiries to:

Wendy Weber, ND, PhD, MPH
National Center for Complementary and Integrative Health (NCCIH)
Telephone: 301-402-1272
Email: [email protected]